Autoantibodies against glucose-regulated protein 78 as serological diagnostic biomarkers in hepatocellular carcinoma

Shao, Qing; Ren, Pengfei; Li, Yang; Peng, Bo; Dai, Liping; Lei, Ningjing; Wu, Yao; Zhao, Gang; Li, Linggen; Zhang, Jianying

doi:10.3892/ijo.2012.1515

Cited by 36 publications

(29 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, there are no data available, to our knowledge that associates autoantibodies against p53 with patients' clinical characteristics. In patients with colorectal cancer (CRC), there is an increase in the prevalence of anti-p53 autoantibodies in carcinoma in-situ (6%) compared with adenomas (1%), indicating that the level of anti-p53 autoantibody increases with CRC [36] hnRNP L Akada et al [42] HSP70, SOD2, and PRDX6 Shao et al [41] Glucose-regulated protein 78 Nomura et al [39] Ku86 Liu et al [40] CENPF, DDX3, HSPA4, HSPA5, VIM, LMNB1, and p53 Pekáriková et al [21] CRT Chen et al [28] Sui1, RalA Wang et al [43] KRT23, AHSG and FTL Wang et al [44] RalA Looi et al [45] HSP60, HSP70 Li et al [35] DDX3, eEF2, AIF, hnRNP A2, PBP, and TIM Chen et al [46] EIF3SI, LDHA, RFC2, and MCART1 Zhang et al [27] IMP1, IMP2, IMP3, p53, c-myc, cyclin B1, survivin and p16 Akere et al [13] p53 Zhou et al [47] HCC-22-5 Takashima et al [48] HSP70, GAPDH, PRX, Mn-SOD Looi et al [49] p16 Yagihashi et al [25] Survivin Su et al [17] IMP2 Himoto et al [19] IMPs Himoto et al [18] IMPs, p53, c-myc, and survivin Zhang et al [24] c-myc, cyclin B1, IMP1, Koc, p53, IMP2, and survivin Soo Hoo et al [50] p53, IMP2, Koc, CENP-F, p90 Le Naour et al [51] CRT, CK8, NDK-A, and ATP5B Zhang et al [23] IMP2, CENPF Zhang et al [20] IMP2 Raedle et al [52] p53 Covini et al [22] Cyclin B1 Imai et al [53] HCC1 TAAs: Tumor-associated antigens; HCC: Hepatocellular carcinoma; IMP: Insulin-like growth factor mRNA-binding; CENPF: Centromere protein F. 9…”

Section: Association Of the Prevalence Of Autoantibodies With The CLImentioning

confidence: 99%

Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma

Huang

2015

WJH

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide. The survival rate after the onset of symptoms is generally less than one year for the late presentation of HCC, and reliable tools for early diagnosis are lacking. Therefore, novel biomarkers for the early detection of HCC are urgently required. Recent studies show that the abnormal release of proteins by tumor cells can elicit humoral immune responses to self-antigens called tumor-associated antigens (TAAs). The corresponding autoantibodies can be detected before the clinical diagnosis of cancer. Therefore, there is growing interest in using serum autoantibodies as cancer biomarkers. In this review, we focus on the advances in research on autoantibodies against TAAs as serum biomarker for detection of HCC, the mechanism of the production of TAAs, and the association of autoantibodies with patients' clinical characteristics.

show abstract

Section: Association Of the Prevalence Of Autoantibodies With The CLImentioning

confidence: 99%

Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma

Huang

2015

WJH

View full text Add to dashboard Cite

show abstract

“…A study by Koomägi et al (18) indicated that GRP78 was overexpressed in human non-small cell lung cancer. Furthermore, a number of previous studies demonstrated that GRP78 was induced and expressed at a high level in brain, prostate, colorectal and gastric cancers, and in HCCs and ureter tumors (10)(11)(12)14,15,17). Using immunohistological staining, RT-PCR and western blotting, the present study revealed that the expression level of GRP78 in human osteosarcoma tissues was higher than that in the normal tissues surrounding the tumors.…”

Section: Tumor Tissue -----------------------------------------------mentioning

confidence: 70%

“…Li et al (20) demonstrated that the knockdown of GRP78 downregulated the expression and activity of matrix metalloproteinase-2 and TIMP metallopeptidase inhibitor-2 in HCC cells. In another study, anti-GRP78 autoantibodies were suggested to be potential diagnostic markers for HCC (11). In view of its importance for the survival of cancer cells, GRP78 could be used as an anticancer drug target.…”

Section: Introductionmentioning

confidence: 99%

“…However, the present study did not review the experimental literature concerning patients with osteosarcoma. In addition, numerous studies have demonstrated that GRP78 represents a concordant mechanism of drug resistance in malignant tumors, and could therefore be applied as a predictor for guiding the treatment for patients (11,(20)(21)(22)(23). The present study aimed to investigate the expression of GRP78 in patients with osteosarcoma, and to analyze the expressional differences in tumor tissue and normal tissue, chemotherapy-and non-chemotherapy-treated patients, and metastatic and non-metastatic tumors.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, an overexpression of GRP78 has been detected in several cancers, including brain, breast, lung, prostate, colorectal and gastric cancer, and in hepatocellular carcinoma (HCC) and ureter tumors (10)(11)(12)(13)(14)(15)(16)(17). These studies also revealed that GRP78 had an important role in the process of metastasis, and that the knockdown of GRP78 inhibited the invasiveness of cancer cells in vitro, and inhibited the growth and metastasis of a malignant tumor allograft model (18,19).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Expression and significance of glucose-regulated protein 78 in human osteosarcoma

Zhang

Wang

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The present study aimed to investigate the expression of glucose-regulated protein 78 (GRP78) in osteosarcoma cells, and analyze the differences in expression between tumor and normal tissues, pre-and post-chemotherapy patients and metastatic and non-metastatic tumors. According to these results, the associations between the expression of GRP78 and tumor growth, metastasis and chemotherapeutics could be determined. Between 2007 and 2012, 60 patients who had been diagnosed with osteosarcoma were selected for the present study. Of these patients, 20 presented with non-metastatic tumors and 40 with metastatic tumors, and 20 had been treated without chemotherapy and 40 with chemotherapy. In addition, 60 specimens obtained from adjacent normal tissues were collected for the control groups. Immunofluorescence staining was used to examine the expression of GRP78 in the different tissues. The total RNA and protein were extracted from crushed tissues and used in the reverse transcription polymerase chain reaction and western blot analysis. GRP78 was primarily located in the intracavity of the endoplasmic reticulum. The expression level of GRP78 in the tumor tissue was higher than that in the normal tissue surrounding the tumor (P<0.01). In addition, the level was higher in the metastatic tumors compared with the non-metastatic tumors (P<0.05), and in the non-chemotherapy-treated patients compared with the chemotherapy-treated patients (P<0.01). The expression level of GRP78 mRNA in the tumor tissue was higher than that in the normal tissue (P<0.01). Furthermore, the level was higher in the metastasis group than in the non-metastasis group (P<0.05), and in the non-chemotherapy group than in the chemotherapy group (P<0.01). The expression level of GRP78 protein was higher in the tumor tissue compared with the normal tissue (P<0.01), in the metastasis group compared with the non-metastasis group (P<0.05), and in the non-chemotherapy group compared with the chemotherapy group (P<0.01). In conclusion, the present study detected the expression of GRP78 in patients with osteosarcoma and revealed a higher expression level in the tumor tissues compared with the normal tissues around the tumor, in the metastasis group compared with the non-metastasis group and in the non-chemotherapy-treated group compared with the chemotherapy-treated group.

show abstract

Structure prediction, expression, and antigenicity of c‐terminal of GRP78

Aghamollaei

Gargari

Ghanei

et al. 2016

Biotech and App Biochem

View full text Add to dashboard Cite

Glucose-regulated protein 78 (GRP78) is a typical endoplasmic reticulum luminal chaperone having a main role in the activation of the unfolded protein response. Because of hypoxia and nutrient deprivation in the tumor microenvironment, expression of GRP78 in these cells becomes higher than the native cells, which makes it a suitable candidate for cancer targeting. Suppression of survival signals by antibody production against C-terminal domain of GR78 (CGRP) can induce apoptosis of cancer cells. The aim of this study was in silico analysis, recombinant production, and characterization of CGRP in Escherichia coli. Structural prediction of CGRP by bioinformatics tools was done and the construct containing optimized sequence was transferred to E. coli T7 shuffle. Expression was induced by isopropyl-β-d-thiogalactoside, and recombinant protein was purified by Ni-NTA agarose resin. The content of secondary structures was obtained by circular dichroism (CD) spectrum. CGRP immunogenicity was evaluated from the immunized mouse sera. SDS-PAGE analysis showed CGRP expression in E. coli. CD spectrum also confirmed prediction of structures by bioinformatics tools. The enzyme-linked immunosorbent assay using sera from immunized mice revealed CGRP as a good immunogen. The results obtained in this study showed that the structure of truncated CGRP is very similar to its structure in the whole protein context. This protein can be used in cancer researches.

show abstract

Autoantibodies against glucose-regulated protein 78 as serological diagnostic biomarkers in hepatocellular carcinoma

Cited by 36 publications

References 44 publications

Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma

Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma

Expression and significance of glucose-regulated protein 78 in human osteosarcoma

Structure prediction, expression, and antigenicity of c‐terminal of GRP78

Contact Info

Product

Resources

About